Cincinnati, Ohio 45219


The standard treatment of surgery followed by radiation therapy can stop tumors from growing in the head and neck region in most patients. However, the cancer can recur or can spread to other parts of the body. Cetuximab is a drug that may delay or prevent tumor growth by blocking certain cellular chemical pathways that lead to tumor development. It was approved by the United States Food and Drug Administration (FDA) in 2006 for the treatment of head and neck cancer. The purpose of this study is to determine how easily cetuximab can be added to treatment with radiation therapy in patients with cutaneous cancer of the head and neck. This study will also look at how well cetuximab added to radiation therapy works over time and how well this treatment is tolerated.

Study summary:

This is a Phase II trial to characterize the feasibility of treating patients with locally advanced cutaneous squamous cell carcinomas of the head and neck with post-operative radiotherapy and cetuximab. Cetuximab has previously been given safely in conjunction with head and neck radiotherapy for mucosal squamous cell carcinoma in multiple phase III trials, and so Phase I data is not necessary here.


Inclusion Criteria: - Pathologically (histologically) proven diagnosis of cutaneous squamous cell carcinoma of the head and neck - Clinical stage >/= T3 or >/= N1, M0 including no distant metastases - Gross total resection of the primary tumor with curative intent must be completed within 7 weeks of registration - Performance status of 0-1 within 2 weeks prior to registration - Age >/= 18 - Adequate labs within 2 weeks prior to registration Exclusion Criteria: - Prior invasive malignancy unless disease free for a minimum of 3 years; noninvasive cancers (For example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible) are permitted even if diagnosed and treated < 3 years ago. Patients with a history of T1-2, N0, M0 resected differentiated thyroid carcinoma are considered eligible. - Prior systemic chemotherapy or anti-epidermal growth factor therapy for the study cancer or for a different prior cancer - Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields



Primary Contact:

Principal Investigator
Michelle Mierzwa, MD
University of Cincinnati

University of Cincinnati Cancer Institute
Phone: 513-584-7698

Backup Contact:


Location Contact:

Cincinnati, Ohio 45219
United States

University of Cincinnati Cancer Institute
Phone: 513-584-7698

Site Status: Recruiting

Data Source:

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.